CRVS

4.43

32.24% 1.08

Handel nachbörslich: 4.43

Corvus Pharmaceuticals Inc (CRVS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$3.35

Offen:

$4.22

24-Stunden-Volumen:

8.83M

Relative Volume:

9.85

Marktkapitalisierung:

$246.77M

Einnahmen:

Nettoeinkommen (Verlust:

$-27.03M

KGV:

-7.9107

EPS:

-0.56

Netto-Cashflow:

$-23.97M

1W Leistung:

+22.38%

1M Leistung:

+50.68%

6M Leistung:

-53.12%

1J Leistung:

+118.23%

1-Tages-Spanne:

$3.93

$4.49

1-Wochen-Bereich:

$3.165

$4.49

52-Wochen-Spanne:

$1.75

$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Firmenname

Corvus Pharmaceuticals Inc

Sektor

Healthcare (1153)

Branche

Biotechnology (676)

Telefon

(650) 900-4520

Adresse

863 MITTEN ROAD, BURLINGAME, CA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-03-25

Neueste SEC-Einreichungen

CRVS's Discussions on Twitter

Vergleichen Sie CRVS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CRVS Corvus Pharmaceuticals Inc	4.43	246.77M	0	-27.03M	-23.97M	-0.56
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.58B	1.06B	-1.28B	16.33
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-02	Eingeleitet	H.C. Wainwright	Buy
2023-08-18	Eingeleitet	Oppenheimer	Outperform
2021-12-01	Fortgesetzt	Jefferies	Buy
2021-05-27	Eingeleitet	Cantor Fitzgerald	Overweight
2021-02-10	Herabstufung	Mizuho	Buy → Neutral
2019-09-12	Eingeleitet	Mizuho	Buy
2019-05-29	Eingeleitet	ROTH Capital	Buy
2017-08-24	Hochstufung	Credit Suisse	Underperform → Neutral
2017-05-01	Herabstufung	Credit Suisse	Neutral → Underperform
2016-04-18	Eingeleitet	Credit Suisse	Outperform
2016-04-18	Eingeleitet	Guggenheim	Buy

Alle ansehen

Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten

May 10, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025

May 09, 2025

Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN

May 09, 2025

Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks

May 09, 2025

CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS S - GuruFocus

May 09, 2025

Corvus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 09, 2025

CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS Stock News - GuruFocus

May 09, 2025

Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased - Asianet Newsable

May 09, 2025

Why Is Corvus Pharmaceuticals Stock Soaring On Friday? - Benzinga

May 09, 2025

Corvus Pharmaceuticals shares surge on positive trial results By Investing.com - Investing.com Nigeria

May 09, 2025

Corvus Pharmaceuticals shares surge on positive trial results - Investing.com

May 09, 2025

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating - marketscreener.com

May 09, 2025

Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo Finance

May 09, 2025

Corvus: Q1 Earnings Snapshot - New Haven Register

May 09, 2025

Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - Benzinga

May 09, 2025

Corvus reports positive phase 1 trial results for atopic dermatitis drug - Investing.com

May 09, 2025

Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket - marketscreener.com

May 09, 2025